Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory J Dore

Showing results (281-290 of 404) with videos related to

Pageof 41
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|October 28, 2022
Prison-based interventions are key to achieving HCV elimination among people who inject drugs in New South Wales, Australia: A modelling studyJack Stone, Aaron G Lim, Gregory J Dore, et al.
Journal of Gastroenterology and Hepatology|November 14, 2013
Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studiesStuart K Roberts, Joanne Mitchell, Reynold Leung, et al.
The Lancet. Global Health|November 5, 2021
Elimination versus mitigation of SARS-CoV-2 in the presence of effective vaccinesMiquel Oliu-Barton, Bary S R Pradelski, Yann Algan, et al.
Nature Immunology|January 14, 2022
Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infectionChansavath Phetsouphanh, David R Darley, Daniel B Wilson, et al.
AIDS (London, England)|June 27, 2020
Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIVSamira Hosseini-Hooshyar, Marianne Martinello, Jasmine Yee, et al.
Journal of Viral Hepatitis|October 27, 2022
Hepatitis C virus-specific immune responses following direct-acting antivirals administered during recent hepatitis C virus infectionJulia L Casey, Gregory J Dore, Jason Grebely, et al.
JHEP Reports : Innovation in Hepatology|July 18, 2025
Prioritising viral hepatitis elimination to prevent hepatocellular carcinoma: A public health approach for effective preventive hepatologyDana Ivancovsky Wajcman, Aina Nicolàs, Camila A Picchio, et al.
Plos One|April 29, 2016
HCV Specific IL-21 Producing T Cells but Not IL-17A Producing T Cells Are Associated with HCV Viral Control in HIV/HCV CoinfectionSonya A MacParland, Saleh M Fadel, Vesna Mihajlovic, et al.
The International Journal on Drug Policy|June 28, 2015
Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis CMaryam Alavi, Tim Spelman, Gail V Matthews, et al.
Gastroenterology|September 29, 2009
Effective treatment of injecting drug users with recently acquired hepatitis C virus infectionGregory J Dore, Margaret Hellard, Gail V Matthews, et al.
Pageof 41

Showing results (281-290 of 404) with videos related to

Sort By:
Pageof 41
Liver International : Official Journal of the International Association for the Study of the Liver|October 28, 2022
Prison-based interventions are key to achieving HCV elimination among people who inject drugs in New South Wales, Australia: A modelling studyJack Stone, Aaron G Lim, Gregory J Dore, et al.
Journal of Gastroenterology and Hepatology|November 14, 2013
Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studiesStuart K Roberts, Joanne Mitchell, Reynold Leung, et al.
The Lancet. Global Health|November 5, 2021
Elimination versus mitigation of SARS-CoV-2 in the presence of effective vaccinesMiquel Oliu-Barton, Bary S R Pradelski, Yann Algan, et al.
Nature Immunology|January 14, 2022
Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infectionChansavath Phetsouphanh, David R Darley, Daniel B Wilson, et al.
AIDS (London, England)|June 27, 2020
Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIVSamira Hosseini-Hooshyar, Marianne Martinello, Jasmine Yee, et al.
Journal of Viral Hepatitis|October 27, 2022
Hepatitis C virus-specific immune responses following direct-acting antivirals administered during recent hepatitis C virus infectionJulia L Casey, Gregory J Dore, Jason Grebely, et al.
JHEP Reports : Innovation in Hepatology|July 18, 2025
Prioritising viral hepatitis elimination to prevent hepatocellular carcinoma: A public health approach for effective preventive hepatologyDana Ivancovsky Wajcman, Aina Nicolàs, Camila A Picchio, et al.
Plos One|April 29, 2016
HCV Specific IL-21 Producing T Cells but Not IL-17A Producing T Cells Are Associated with HCV Viral Control in HIV/HCV CoinfectionSonya A MacParland, Saleh M Fadel, Vesna Mihajlovic, et al.
The International Journal on Drug Policy|June 28, 2015
Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis CMaryam Alavi, Tim Spelman, Gail V Matthews, et al.
Gastroenterology|September 29, 2009
Effective treatment of injecting drug users with recently acquired hepatitis C virus infectionGregory J Dore, Margaret Hellard, Gail V Matthews, et al.
Pageof 41